Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ACOR | Acorda Therapeutics, Inc.

Index- P/E- EPS (ttm)-17.09 Insider Own0.10% Shs Outstand1.24M Perf Week5.05%
Market Cap20.29M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.23M Perf Month-5.39%
Income-20.90M PEG- EPS next Q- Inst Own25.80% Short Float / Ratio0.55% / 0.72 Perf Quarter21.86%
Sales116.90M P/S0.17 EPS this Y65.80% Inst Trans-53.95% Short Interest0.01M Perf Half Y26.91%
Book/sh54.64 P/B0.29 EPS next Y- ROA-5.50% Target Price- Perf Year123.96%
Cash/sh19.46 P/C0.80 EPS next 5Y46.00% ROE-26.60% 52W Range5.22 - 24.80 Perf YTD1.80%
Dividend- P/FCF- EPS past 5Y34.30% ROI-14.90% 52W High-37.06% Beta1.38
Dividend %- Quick Ratio1.60 Sales past 5Y-27.40% Gross Margin81.30% 52W Low198.93% ATR1.17
Employees111 Current Ratio2.10 Sales Q/Q-4.50% Oper. Margin6.30% RSI (14)56.22 Volatility5.39% 8.97%
OptionableNo Debt/Eq2.59 EPS Q/Q86.40% Profit Margin-17.90% Rel Volume2.82 Prev Close15.80
ShortableYes LT Debt/Eq2.59 EarningsAug 08 AMC Payout- Avg Volume9.39K Price15.61
Recom2.00 SMA2011.24% SMA502.71% SMA20010.01% Volume26,467 Change-1.20%
Date Action Analyst Rating Change Price Target Change
Jun-17-21Upgrade H.C. Wainwright Neutral → Buy $5 → $10
Aug-14-19Downgrade H.C. Wainwright Buy → Neutral $31 → $6
May-23-19Initiated Wedbush Neutral
Dec-11-18Downgrade Goldman Neutral → Sell
Aug-07-18Reiterated Stifel Hold $15 → $25
Feb-16-18Upgrade Piper Jaffray Neutral → Overweight
Jan-17-18Reiterated H.C. Wainwright Buy $34 → $31
Nov-28-17Resumed Piper Jaffray Neutral $22
Nov-16-17Downgrade Stifel Buy → Hold $26 → $15
Nov-16-17Downgrade Raymond James Mkt Perform → Underperform
Aug-28-23 12:42PM
Aug-08-23 04:21PM
Aug-02-23 08:00AM
Aug-01-23 08:00AM
05:08PM Loading…
Jun-28-23 05:08PM
Jun-26-23 08:23AM
Jun-05-23 09:06AM
Jun-02-23 04:01PM
May-31-23 04:01PM
May-30-23 08:00AM
May-12-23 05:28AM
May-11-23 04:29PM
07:00AM Loading…
May-10-23 07:00AM
May-08-23 07:00AM
May-04-23 09:41AM
Apr-24-23 08:00AM
Apr-03-23 08:00AM
Mar-27-23 08:00AM
Mar-09-23 07:00AM
Mar-07-23 07:00AM
Mar-06-23 03:43PM
Feb-14-23 04:46PM
Jan-31-23 04:01PM
Jan-05-23 04:20PM
Dec-22-22 08:00AM
Dec-20-22 05:30PM
Dec-05-22 07:01AM
08:12AM Loading…
Nov-19-22 08:12AM
Nov-11-22 09:52AM
Nov-04-22 09:25AM
Nov-01-22 04:01PM
Oct-27-22 07:00AM
Oct-25-22 04:01PM
Oct-21-22 07:00AM
Oct-19-22 07:00AM
Oct-18-22 07:00AM
Oct-16-22 04:48PM
Oct-10-22 06:30AM
Sep-08-22 04:01PM
Aug-29-22 07:00AM
Aug-19-22 08:00AM
Aug-04-22 04:01PM
Jul-28-22 04:01PM
Jun-16-22 09:31AM
May-11-22 04:01PM
May-04-22 04:01PM
Mar-09-22 04:01PM
Feb-24-22 05:00PM
Jan-04-22 07:11AM
Jan-03-22 04:01PM
Nov-09-21 04:01PM
Nov-02-21 07:00AM
Sep-09-21 08:01AM
Aug-05-21 05:45PM
Jul-30-21 04:01PM
Jul-27-21 03:02PM
Jul-23-21 07:28AM
Jul-22-21 04:01PM
Jun-18-21 10:46PM
Jun-16-21 07:00AM
May-06-21 05:15PM
Apr-29-21 04:30PM
Apr-27-21 12:00PM
Apr-20-21 09:46AM
Apr-12-21 07:00AM
Apr-01-21 07:51AM
Mar-12-21 10:01AM
Mar-11-21 08:52AM
Mar-10-21 11:30AM
Mar-08-21 11:12PM
Mar-05-21 08:15AM
Mar-04-21 05:45PM
Mar-03-21 12:52PM
Mar-02-21 08:43AM
Feb-26-21 10:10AM
Feb-25-21 07:00AM
Feb-19-21 07:00AM
Feb-11-21 11:12AM
Feb-10-21 10:21AM
Feb-08-21 12:40PM
Feb-04-21 11:48AM
Feb-02-21 03:23PM
Feb-01-21 10:28AM
Jan-28-21 10:12AM
Jan-27-21 11:13AM
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COHEN RONPresident and CEOMar 17Buy0.6510,0006,500149,757Mar 20 04:29 PM
COHEN RONPresident and CEOMar 16Buy0.6010,1566,094139,757Mar 20 04:29 PM